article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin. In-house manufacturing the norm.

Insulin 328
article thumbnail

Key senators make a big pivot on bipartisan insulin cost proposal

STAT News

WASHINGTON — Amid a scramble to assemble a health care policy package in the Senate, a pair of key senators have significantly changed a proposal to cap insulin costs. The new legislation by Senate Diabetes Caucus co-chairs Sens. Jeanne Shaheen (D-N.H.) Jeanne Shaheen (D-N.H.) Read the rest…

Insulin 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tjoapack and Biopharma: Our Packaging Options

Pharma Packaging Solutions

Biopharma Packaging from Tjoapack Biopharmaceutical technology is advancing every day as scientists work to create new, better treatments for diseases that millions struggle with on a daily basis. With biologic treatments becoming ever more available, the need for smart, reliable biopharma packaging is on the rise.

article thumbnail

What Are Biopharmaceuticals?

Pharma Packaging Solutions

Hormones (such as insulin, glucagon, and growth hormone, to name a few) are produced by recombinant DNA, as are blood factors, thrombolytic agents, interferons, monoclonal antibodies, therapeutic enzymes, and more. We offer a variety of packaging services, including vial and ampule labeling, pharmaceutical kit assembly, and more.

article thumbnail

Top 15 Diabetes Drugs in 2023 by 2022 Sales Statistics

XTalks

In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6 percent in the US, impacted by prior formulary losses as well as “erosion of the basal insulin market,” the company said in the statement. In its 2022 financial report, Sanofi reported that sales of the long-acting insulin dropped 27.6

Sales 52
article thumbnail

Roche debuts smart glucose monitor for hospital use

pharmaphorum

” The Android-powered device can run certified third-party software, initially shipping with a handful of apps including Glytec’s Glucommander insulin-dosing software under the terms of a deal announced today.

Insulin 128
article thumbnail

Does anyone really believe pharma cares what people think?

World of DTC Marketing

When the CEO of J&J is awarded a compensation package over $20 million, pharma is once again saying, “above all, we’re a business. Yes, pharma is big business, but if a corporation is the people who work there, how can so many stay silent while people pay outrageous prices for insulin and other drugs?

Insulin 183